Aspen Pharmacare

Tweet this page
<
2018
2019
2020
2021
2022
2023
>
No longer registered as of 14 Sep 2024 - Registration as it was on 12 Sep 2023
How to read and use this data card.
Download this datacard

Overview

WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.

Lobbying Costs

10,000€

Financial year: Jul 2022 - Jun 2023

Lobbyists (Full time equivalent)

0.1 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Aspen Pharmacare   (ASP)

    EU Transparency Register

    204680631588-97 First registered on 22 May 2018

    Goals / Remit

    Aspen Pharmacare is a South-African pharmaceutical company.
    Aspen operates with an established business presence in approximately 50 countries and supply products in more than 150 countries. We have a proud heritage dating back more than 160 years and are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.

    We are a leading global player in specialty and branded pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to benefit the lives of patients using our products in more than 150 countries.

    Aspen has identified Anaesthetics, High Potency & Cytotoxics, Antthrombotics and Nutritionals as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.

    We operate 25 manufacturing facilities across 17 sites.

    Main EU files targeted

    Aspen currently follows European policies, legislative files related to our Pharmaceuticals and any EU project(mainly in Anesthetesia and Oncology). We are particularly interested in European initiatives to support medicine affordability to patients and any initiatives to support production investment in the European countries.
    Our domains of interest includes also Data Protection Regulation, Brexit consequences, Pharmaceutical Industry strategy, and EU pricing & trade Policy.

    Address

    Head Office
    Aspen Place 9 Rydall Vale Park Douglas Saunders Drive, La Lucia Ridge
    Durban Gateway, 4321 - P O Box 25125
    SOUTH AFRICA
    EU Office
    Montgelasstrasse 14
    München 81679
    GERMANY

    Website

    http://aspenpharma.com/

  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    10%1

    Lobbyists (Full time equivalent)

    0.1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 15 Jan 2025

    Name Start date End Date
    Mr Fabrice JOVER 29 May 2018 29 May 2019

    Complementary Information

    Current Position: Market Access & Tender Management Lead; overviewing EU Pharma Activities like Revision of EU general pharmaceutical legislation; EU Proposed directive on corporate sustainability due diligence, Relevance of the Green Deal,

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    https://www.aspenpharma.com/we-care/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jul 2022 - Jun 2023

    Lobbying costs for closed financial year

    10,000€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    0€ - 10,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    Application of King IV and compliance with the Companies
    Act
    The Group continuously strives to enhance its application of King IV and to ensure its ongoing compliance with the
    South African Companies Act, 2008 (“Companies Act”). The application of the King IV principles and adoption of the various recommendations are published online.

    https://www.aspenpharma.com/corporate-governance/

    Other activities

    Aspen is dedicated to work with EU Authorities and to build sustainable partnership with the EU countries. Aspen has an strong supply presence in France at Notre-Dame de Bondeville, in Germany at Bad Odesloe and in Netherlands at Oss. Commercial presence in all EU countries.

  • Meetings

    Meetings

    None declared

Download this datacard